

Freedom of Information Request	FOI 22-223	8 <sup>th</sup> June 2022
--------------------------------	------------	---------------------------

**Q1. How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from January to April 2022:**

Please find below the quantities dispensed in the Health Board's pharmacy for the period January to April 2022. Please note the Health Board is only able to supply information by quantity and not by the number of patients treated:

- **Aflibercept**
- **Bevacizumab**
- **Brolucizumab**
- **Dexamethasone**
- **Fluocinolone acetonide**
- **Ranibizumab**

Type	Qty
AFLIBERCEPT (EYLEA) 3.6 mg in 0.09mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	3811
DEXAMETHASONE 700 micrograms Implant 1 Implant Pack	3
RANIBIZUMAB 1.65 mg in 0.165mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	834

**Q2. Please provide the number of injections/implants by eye condition for the four-month period from January to April 2022.**

Please refer to Question 1.

Eye Conditions			
Treatment	Wet Age-Related Macular Degeneration wAMD	Diabetic Macular Degeneration DMO	Retinal Vein Occlusion RVO
Aflibercept			
Bevacizumab			
Brolucizumab			
Dexamethasone			
Fluocinolone acetonide			
Ranibizumab			